Novacyt: Three Executives Report Stock Purchases in Late March 2026
Novacyt S.A. has announced that it was notified of ordinary share purchases made by three executives in late March 2026, as part of the disclosure obligations applicable to persons discharging managerial responsibilities.
Lyn Rees, CEO, acquired 73,379 shares at an average price of 0.3899 euros per share. John Brown, Chairman, purchased 73,762 shares at the same average price of 0.3899 euros. Ian Gilham, Non-Executive Director, acquired 28,750 shares at an average price of 0.34415 pounds per share. According to the company, the transactions of Lyn Rees and John Brown were carried out on Euronext on March 26 and 27, 2026. Ian Gilham's transaction was executed on AIM on March 27, 2026. Novacyt is listed on Euronext Growth in Paris under the ticker ALNOV and on AIM in London under the ticker NCYT.
Notification of Transactions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
These transactions are subject to notification under the disclosure obligations for transactions conducted by persons discharging managerial responsibilities within the company. Novacyt S.A. is listed on Euronext Growth in Paris under the ticker ALNOV and on AIM, the alternative investment market of the London Stock Exchange, under the ticker NCYT.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: FY2025
Key reported figures
Revenue: 20 MGBP
EBITDA: -7,8 MGBP
Net income: -22,9 MGBP
Outlook / guidance
Management commentary: Nos perspectives pour l'exercice 26 semblent solides, avec un objectif de croissance du chiffre d'affaires à deux chiffres d'une année sur l'autre et la poursuite de notre trajectoire vers une rentabilité de l'EBITDA.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
